Meeting
2021 ASCO Annual Meeting
EPIK-P2: A prospective phase 2, double-blind, randomized, placebo-controlled study of alpelisib in pediatric and adult patients (Pts) with PIK3CA-related overgrowth spectrum (PROS).
Authors
Guillaume Canaud
Hȏpital Necker, Université de Paris, Paris, France
Guillaume Canaud , Juan Carlos López Gutiérrez , Adrienne M. Hammill , Lisa Weibel , Ghislaine Vincent , Séverine Niglis , Michaela Paul , Denise M. Adams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04589650
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS3160)
DOI
10.1200/JCO.2021.39.15_suppl.TPS3160
Abstract #
TPS3160
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.
First Author: William D. Tap
Poster
2015 ASCO Annual Meeting
A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer.
First Author: Ingrid A. Mayer
Poster
2023 ASCO Annual Meeting
ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.
First Author: Andrew Peter Dean
Poster
2022 ASCO Annual Meeting
Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA-mutant, hormone receptor–positive breast cancer.
First Author: Sherry Shen